Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01296932
Recruitment Status : Completed
First Posted : February 16, 2011
Results First Posted : August 20, 2020
Last Update Posted : August 20, 2020
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Adult patients with chronic lymphocytic leukaemia who experience a relapse after at least two prior treatment regimens may be enrolled in this trial. The trial will examine whether monotherapy with BI 836826 is safe and tolerable at escalating dose levels.

Condition or disease Intervention/treatment Phase
Leukemia, Lymphocytic, Chronic, B-Cell Drug: BI 836826 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia
Actual Study Start Date : February 11, 2011
Actual Primary Completion Date : May 30, 2017
Actual Study Completion Date : July 10, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Patients with relapsed CLL
Patients with relapsed CLL after at least two prior treatment regimens will receive BI 836826.
Drug: BI 836826
Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.




Primary Outcome Measures :
  1. Number of Patients With Dose-Limiting Toxicities Adverse Events (DLTs) [ Time Frame: 14 days after first administration of BI836826 (MTD evaluation period) ]
    Dose-Limiting Toxicities (DLTs) were defined as any drug-related non-haematologic adverse event of Common Terminology Criteria for AE (CTCAE) Grade 3 or higher, except infusion related reactions associated with the administration of BI 836826. In addition complications due to haematologic AEs were considered as DLTs and were added in more detail in an amendment later on.

  2. Maximum Tolerated Dose (MTD) [ Time Frame: 14 days after first administration of BI836826 (MTD evaluation period) ]
    The maximum tolerated dose (MTD) was defined as the highest dose of BI 836826 studied for which the incidence of DLT was no more than 17% (i.e. 1 out of 6 patients) during the first treatment cycle. For those patients who received more than 1 cycle of BI 836826, all AEs corresponding to the DLT were considered for the purpose of confirming the MTD and for the selection of the recommended dose for treatment of the expansion cohort and for further development. All DLTs, occurring during the first or repeated treatment cycle were reported as significant AEs. As it was not possible to recruit a sufficient number of patients whilst the first part of the trial was still in progress, the recruitment was ended by the sponsor before the MTD or optimal biological dose (OBD) was reached.


Secondary Outcome Measures :
  1. Best Percentage Change From Baseline in Number of Lymphocytes in the Peripheral Blood [ Time Frame: baseline and ≥8 day after a completed infusion of a cycle and before Chronic Lymphocytic Leukemia (CLL) therapy; data collected up to cut-off date 26Oct2016, Up to 1809 days ]
    In most patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), malignant B-cells represent the majority of lymphocytes in the peripheral blood. Reduction of CLL-cells was assessed in the peripheral blood by absolute lymphocyte count, and flow cytometry. The number of lymphocytes in the peripheral blood was analysed in terms of the best percentage change from baseline until start of subsequent CLL therapy or progressive disease (PD).

  2. Number of Patients With Improved Haemoglobin Count for at Least Two Subsequent Response Assessments [ Time Frame: ≥8 day after a completed infusion of a cycle and before Chronic Lymphocytic Leukemia (CLL) therapy; data collected up to cut-off date 26Oct2016, Up to 1809 days ]
    In patients with haemoglobin counts below the limits of normal at baseline, improvement in this count during therapy potentially indicated a benefit for the patient. Number of patients with improved haemoglobin count for at least two subsequent response assessments which fulfil International Workshop on Chronic Lymphocytic Leukemia (IWCLL) response criteria for Complete Remission (CR) or Partial Remission (PR). The response was assessed before Progressive Disease (PD) or start of new Chronic Lymphocytic Leukaemia (CLL) therapy.

  3. Number of Patients With Improved Platelet Count for at Least Two Subsequent Response Assessments [ Time Frame: ≥8 day after a completed infusion of a cycle and before Chronic Lymphocytic Leukemia (CLL) therapy; data collected up to cut-off date 26Oct2016, Up to 1809 days ]
    In patients with platelet counts below the limits of normal at baseline, improvement in this count during therapy potentially indicated a benefit for the patient. Number of patients with improved platelet count for at least two subsequent response assessments which fulfil International Workshop on Chronic Lymphocytic Leukemia (IWCLL) response criteria for Complete Remission (CR) or Partial Remission (PR). The response was assessed before Progressive Disease (PD) or start of new Chronic Lymphocytic Leukaemia (CLL) therapy.

  4. Number of Patients With Improved Neutrophil Count for at Least Two Subsequent Response Assessments [ Time Frame: ≥8 day after a completed infusion of a cycle and before Chronic Lymphocytic Leukemia (CLL) therapy; data collected up to cut-off date 26Oct2016, Up to 1809 days ]
    In patients with neutrophil count below the limits of normal at baseline, improvement in this count during therapy potentially indicated a benefit for the patient. Number of patients with improved neutrophil count for at least two subsequent response assessments which fulfil International Workshop on Chronic Lymphocytic Leukemia (IWCLL) response criteria for Complete Remission (CR) or Partial Remission (PR). The response was assessed before Progressive Disease (PD) or start of new Chronic Lymphocytic Leukaemia (CLL) therapy.

  5. Best Overall Response According to 'International Workshop on Chronic Lymphocytic Leukemia' (IWCLL) Criteria [ Time Frame: Data collected up to cut-off date 26Oct2016 until Progressive disease (PD) to start of next Chronic Lymphocytic Leukaemia (CLL) therapy, Up to 1809 days. ]
    Response was assessed according to the IWCLL (International Workshop on Chronic Lymphocytic Leukemia) guidelines based on laboratory data from the peripheral blood and clinical examination by the investigator after each cycle prior to administration of the next dose of BI 836826, at the end of the treatment (EOT) visit, and at all Follow-up Visits. Best overall response will be analysed descriptively. Frequency distributions will be used to examine this endpoint.

  6. Progression-free Survival [ Time Frame: Data collected up to cut-off date 26Oct2016, Up to 1809 days. ]

    Progression-free survival (PFS) was defined as the time from the first administration of BI 836826 until disease progression or death, whichever occurred first. Disease progression= At least one of the following:

    • 50+% increase in blood lymphocytes over baseline with an absolute number of B-lymphocytes of at least 5x109/L
    • Progression of lymphadenopathy
    • 50+% increase in the previously noted enlargement of the liver or new appearance of hepatomegaly
    • 50+% increase in the previously noted enlargement of the spleen or new appearance of splenomegaly
    • 50+% Decrease of platelet counts or to less than 100x109/L secondary to CLL and unrelated to autoimmune cytopenia
    • Decrease of haemoglobin levels by more than 20 g/L, or to less than 100 g/L secondary to CLL and unrelated to autoimmune cytopenia T Transformation to a more aggressive histology, e.g. Richter syndrome.

  7. Failure-free Survival [ Time Frame: Data collected up to cut-off date 26Oct2016, Up to 1809 days. ]

    Failure-free survival (FFS) was defined as the time from the first administration of BI 836826 until disease progression or death, or start of next Chronic Lymphocytic Leukemia (CLL) therapy, whichever occurred first. Disease progression= At least one of the following:

    • 50+% increase in blood lymphocytes over baseline with an absolute number of B-lymphocytes of at least 5x109/L
    • Progression of lymphadenopathy
    • 50+% increase in the previously noted enlargement of the liver or new appearance of hepatomegaly
    • 50+% increase in the previously noted enlargement of the spleen or new appearance of splenomegaly
    • 50+% Decrease of platelet counts or to less than 100x109/L secondary to CLL and unrelated to autoimmune cytopenia
    • Decrease of haemoglobin levels by more than 20 g/L, or to less than 100 g/L secondary to CLL and unrelated to autoimmune cytopenia T Transformation to a more aggressive histology, e.g. Richter syndrome.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Diagnosis of relapsed or refractory chronic lymphocytic leukaemia.
  2. At least two prior treatment regimens for chronic lymphocytic leukaemia.
  3. At least one criterion for active disease as defined by the International Workshop on CLL.
  4. Absolute lymphocyte count lower than 200 x 10^9/l .
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2.
  6. Age 18 years or older.
  7. Written informed consent which is consistent with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) guidelines and local legislation.

Exclusion criteria:

  1. Treatment with anti Cluster of Differentiation (CD) 20 therapy within 4 weeks, or alemtuzumab within 8 weeks, or any cytotoxic antileukemia therapy within 2 weeks, Ibrutinib or Idelalisib within 1 week prior to the first administration of the trial drug.
  2. Prior allogeneic stem cell transplantation.
  3. Active autoimmune haemolytic anemia.
  4. Active autoimmune thrombocytopenia.
  5. Known transformation to an aggressive B-cell malignancy.
  6. Concurrent treatment with relevant doses of systemic glucocorticosteroids.
  7. Prior history of malignancy other than chronic lymphocytic leukaemia (exceptions to this rule are defined in the clinical trial protocol).
  8. Aspartate aminotransferase or alanine aminotransferase > 2.5 x upper limit of normal.
  9. Total bilirubin > 1.5 x upper limit of normal.
  10. Absolute Neutrophil Count < 1.000/µl.
  11. Platelets < 25.000/µL.
  12. Estimated Glomerular Filtration Rate <45 mL/min.
  13. Proteinuria Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher.
  14. Significant concurrent disease.
  15. Any infectious disease requiring treatment at the time of enrolment or within the previous 2 weeks.
  16. Hepatitis B or C.
  17. Human Immunodeficiency Virus (HIV) infection.
  18. Cytomegalovirus (CMV) viremia.
  19. Women of childbearing potential not using a highly effective method of birth control during the trial until one year after the last dose.
  20. Pregnancy or breast feeding.
  21. Known or suspected active alcohol or drug abuse.
  22. Treatment with another investigational drug within the past four weeks before start of therapy or concomitantly with this trial.
  23. Prior treatment with BI 836826.
  24. Patients unable to comply with the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01296932


Locations
Layout table for location information
Belgium
Brussels - UNIV Saint-Luc
Bruxelles, Belgium, 1200
Edegem - UNIV UZ Antwerpen
Edegem, Belgium, 2650
UNIV UZ Gent
Gent, Belgium, 9000
France
INS Paoli-Calmettes
Marseille, France, 13273
CTR Investigation Clinique, onco, Montpellier
Montpellier Cedex 5, France, 34295
INS Universitaire du Cancer
Toulouse, France, 31059
Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Germany, 60590
Universitätsklinikum Heidelberg
Heidelberg, Germany, 69120
Universitätsklinikum Köln (AöR)
Köln, Germany, 50937
Universitätsklinikum Ulm
Ulm, Germany, 89081
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  Study Documents (Full-Text)

Documents provided by Boehringer Ingelheim:
Statistical Analysis Plan  [PDF] October 13, 2016
Study Protocol  [PDF] March 4, 2015

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01296932    
Other Study ID Numbers: 1270.1
2010-021488-34 ( EudraCT Number )
First Posted: February 16, 2011    Key Record Dates
Results First Posted: August 20, 2020
Last Update Posted: August 20, 2020
Last Verified: August 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
BI 836826
Antineoplastic Agents, Immunological
Antineoplastic Agents